CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, announced today that Andrew Hirsch, BIND’s president and chief executive officer, will present at the JMP Securities Life Sciences Conference 2015 on Tuesday, June 23, 2015 at 11:30 a.m. ET at the St. Regis hotel in New York City.
Help employers find you! Check out all the jobs and post your resume.
